F atty liver disease (FLD) has become the most common liver disease in the Western world, affecting approximately 30% of adults in the United States. (1, 2) The disease is characterized by accumulation of hepatic fat, which over time can cause inflammation (steatohepatitis) and, ultimately, endstage liver disease (cirrhosis, liver cancer).
(1) Obesity is the major risk factor for FLD, and the increased prevalence of the disorder mirrors the increase in adiposity. (1) Other risk factors for FLD include a high intake of alcohol, a sedentary lifestyle, and a diet rich in refined sugars. (1, 3, 4) Apart from these risk factors, genetics plays an important role in FLD development. Several studies report clustering of the disease in families. (5, 6) The first genome-wide association study (GWAS) for FLD found a common variant in patatin-like phospholipase domain-containing protein 3 (PNPLA3; I148M) that was associated with a 2-to 3-fold increase in hepatic triglyceride content (HTGC), as measured by proton magnetic resonance spectroscopy ( 1 H-MRS). (7) A subsequent GWAS, which used computerized tomography (CT) to assess HTGC, replicated the association with PNPLA3 and identified four additional loci (NCAN, LYPLAL1, GCKR, and protein phosphatase 1 regulatory subunit 3B [PPP1R3B]) that were associated with hepatic steatosis (HS). (8) Three of these loci (NCAN, LYPLAL1, and GCKR) were also associated with histological evidence of nonalcoholic liver disease (NAFLD). The fourth locus, PPP1R3B (defined by the single-nucleotide polymorphism [SNP] , rs4240624, which is located 175 kilobases [kb] upstream of PPP1R3B) was strongly associated with HTGC (P 5 10 -18
), but not with histologically determined FLD. Thus, PPP1R3B may be associated with a benign form of HS that does not progress to steatohepatitis. (8) Speliotes et al. (8) noted that the discrepant effects of variation in PPP1R3B on liver fat and histological FLD may have other explanations. The apparent discrepancy may represent a statistical artifact: either a false-positive association with liver fat or a falsenegative association with histological indices of disease. Alternatively, genetic variation in PPP1R3B locus may be associated with other factors, such as iron or glycogen, that affect hepatic x-ray attenuation independently of HTGC. (9) The nature of the association between PPP1R3B and HS has important implications for FLD. If rs4240624 confers a benign form of HS, then liver TG per se is not pathogenic, and other factors must explain the progression of FLD that occurs in a subset of affected individuals. Subsequent studies replicated the association between rs4240624 and liver fat measured by hepatic xray signal attenuation (10) and by ultrasound. (11) These findings make false-positive association unlikely. They also support the contention that variation in PPP1R3B is associated with HTGC, rather than glycogen, although neither CT nor ultrasound directly measures liver fat content. Gorden et al. (12) failed to find an association between rs4240624 and FLD using histologically determined liver fat content. Therefore, the relationship between the PPP1R3B and liver fat content remains equivocal. The notion that rs4240624 is not associated with histological FLD also requires confirmation. In the study reported by Speliotes et al., (8) the sample that was available for association with NAFLD (n 5 592) was much smaller than the sample used for analysis of HTGC (n 5 7176); thus, the possibility of a falsenegative association cannot be excluded.
The close proximity of rs4240624 to PPP1R3B raises the possibility that the association between the SNP and hepatic x-ray attenuation is attributed to differences in hepatic glycogen rather than TG. PPP1R3B encodes a 285-residue protein that plays a key role in hepatic glycogen synthesis (13) (14) (15) (Fig. 1 ). PPP1R3B binds both protein phosphatase 1 (PP1) and glycogen (Fig. 1A) . PP1 then dephosphorylates and activates glycogen synthase, which catalyzes the addition of UDP-glucose to glycogen (Fig. 1B) . PP1 also dephosphorylates glycogen phosphorylase, inactivating the enzyme that catalyzes release of glucose from glycogen. (16) Thus, the overall effect of PPP1R3B is to promote formation of glycogen. (16) Here, we tested the hypothesis that the association
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between rs4841132 (a proxy variant in complete linkage with rs4240624) and hepatic x-ray attenuation is attributed to changes in hepatic glycogen rather than triglyceride (TG) content. Given that excessive glycogen accumulation is known to cause liver damage in patients with glycogen storage diseases, (17) we also tested whether rs4841132 confers susceptibility to liver disease. Finally, to confirm that the changes observed in hepatic x-ray attenuation are consistent with effects of alteration in hepatic PPP1R3B activity, we altered expression of the protein in mice and determined the effects on hepatic glycogen and TG content.
Materials and Methods
Studies were approved by institutional review board and ethics committees of the University of Texas (15) (B) Schematic of hepatic glycogen metabolism and the function of PPP1R3B. Glucose taken up by the liver is phosphorylated and then converted to UDP-glucose before being incorporated into glycogen by glycogen synthase. Glycogen phosphorylase breaks down glycogen, releasing glucose-1-phosphate. PPP1R3B targets PP1 to glycogen synthase and glycogen phosphorylase. PP1 then dephosphorylates these enzymes, leading to activation of glycogen synthase, and deactivation of glycogen phosphorylase. The overall effect of PPP1R3B is to promote glycogen formation. (C) Genomic region flanking rs4841132 (500 kb). The diamonds indicate individual genetic variants. LD of the variants with rs4841132 (R 2 ) is given on the y-axis (left), and the recombination hotspots are shown in blue with the recombination rates provided on y-axis (right). Note that both rs4841132 and rs4240624 are located in the liver-specific lncRNA LOC157273 (exon 2 and intron 2, respectively).
Southwestern Medical Center and Copenhagen and were conducted according to the Declaration of Helsinki. Written informed consent was obtained from all participants.
HUMAN SUBJECTS
We included participants from the Dallas Heart Study (DHS), the Dallas Liver Study, the Copenhagen City Heart Study (CCHS), and the Copenhagen General Population Study (CGPS).
The DHS is a multiethnic, probability-based sample of Dallas County residents that was collected between 2000 and 2002 (18) and 2007 and 2009. Ethnicity was self-reported in accord with U.S. census categories. For this study, we included 2,674 DHS participants in whom HTGC was measured using 1 H-MRS, and 1,275 additional individuals for the analysis of serum alanine aminotransferase (ALT) levels, and for use as controls for the Dallas Liver Study.
The Dallas Liver Study is a multiethnic sample of patients with liver disease of nonviral etiology. Participants were recruited from liver clinics at UT Southwestern and Parkland Health and Hospital System in Dallas, Texas. Participants completed a questionnaire on ethnic/racial background, medical history, lifestyle factors, and family history of liver disease and other diseases. Additional clinical information was extracted from medical records by a trained technician. We included all blacks, European-Americans, and Hispanic-Americans (n 5 514). As healthy controls, we used 514 age-matched and ethnicitymatched participants from the DHS. All individuals with a known etiology to their liver disease were not included.
The CCHS and CGPS are prospective studies of the Danish general population initiated in 1976 and 2003, respectively. (19) All participants from the CCHS and CGPS were white and of Danish descent, as determined by the National Danish Civil Registration System. We combined the CCHS and CGPS into one cohort, totaling 107,447 indivdiuals (Copenhagen Cohort). Individuals with the following International Classification of Diseases (ICD) codes were included: ICD8: 57109 (alcoholic cirrhosis); 57111 (nonalcoholic steatohepatitis); 57119 (fatty liver); 57192 (unspecified cirrhosis); and 57199 (nonalcoholic cirrhosis) and ICD10: K70.3 (alcoholic cirrhosis); K74.0 (fibrosis or cirrhosis); K74.6 (unspecified cirrhosis); K76.0 (fatty liver); and K76.9 (liver disease, unspecified). These ICD codes were selected because they are the ones most likely to be used in patients with liver disease of unknown etiology. Data were collected from the National Danish Patient Registry and the National Danish Causes of Death Registry from January 1, 1977 to November 10, 2014. The National Danish Patient Registry has information on all patient contacts with clinical hospital departments in Denmark, including emergency wards and outpatient clinics (from 1994). The National Danish Causes of Death Registry contains data on the causes of all deaths in Denmark, as reported by hospitals and general practitioners. The diagnoses were combined into a dichotomous liver disease endpoint. In total, 1,025 participants in the Copenhagen Cohort had a diagnosis of liver disease, defined by ICD codes as described above.
MEASUREMENT OF HTGC AND CT x-RAY ATTENUATION
HTGC was measured in the DHS using 1 H-MRS as described. (20) Hepatic CT attenuation was measured in 1,572 participants from the CGPS. A random sample of participants from the CGPS was invited to undergo a CT scan of the thorax and upper abdomen (Aquilion One; Toshiba Medical Systems Corporation, Tokyo, Japan). For liver fat assessment, a single, noncontrast, 16-cm volume scan of the upper abdomen was acquired and reconstructed using AIDR3D (Bodyfilter FC12). (21) CT/x-ray attenuation in liver segments 5-6 was measured using circular 1.5 cm 2 regions of interest.
SUPPLEMENTAL METHODS
See the Supplemental Methods for details on (1) other measurements and genotyping; (2) generation of Ppp1r3b knockout (KO) mice; (3) generation of mice lacking a 10.6-kb region corresponding to LOC157273; (4) animal experimental procedures; (5) generation of Adeno-PPP1R3B and overexpression of PPP1R3B in mice; (6) transfection of cells with LOC157273 and PPP1R3B; (7) RT-PCR and RNAsequencing; and (8) statistical analysis.
Results
Baseline characteristics of the cohorts used in this study are shown ( Table 1 ). The DHS and Dallas Liver Study are multiethnic, and the Copenhagen Cohort is 100% white Europeans. The frequency of rs4841132-A was 9% in whites, 12% in blacks, and 24% in HispanicAmericans.
ASSOCIATION BETWEEN RS4841132 AND HEPATIC X-RAY ATTENUATION
Previously, rs4240624 was found to be associated with HTGC. (8) Analysis of SNPs within the region revealed another variant, rs4841132 that is 635 base pairs (bp) downstream of rs4240624. The two SNPs are in complete linkage disequilibrium (LD; Fig. 1C ). rs4841132 is located in exon 2 of the major transcript of an intergenic long noncoding RNA (lncRNA), LOC157273, which is located 175 kb upstream of PPP1R3B (Fig. 1C ). Rs4841132-A (minor allele) was associated with increased hepatic x-ray attenuation among 1,572 participants from the Copenhagen Cohort ( Fig. 2A, left) . Mean Hounsfield units (HU) were 58.8, 60.6, and 63.2 for GG-homozygotes, GAheterozygotes, and AA-homozygotes, respectively (P trend 5 4 3 10 -5 ). To assess changes in attenuation due to differences in HTGC, we examined the same population after stratifying by the steatogenic PNPLA3 (I148M) genotype ( Fig. 2A) . As expected, 148M was associated with decreased x-ray attenuation (P trend 5 3 3 10 -4
). The absolute per-allele effect size on x-ray attenuation of rs4841132-A was approximately twice that of PNPLA3 (148M; 12.4 vs. 21.4 HU per allele). Thus, the Aallele would be predicted to be associated with a substantial reduction in HTGC.
ASSOCIATION BETWEEN RS4841132 AND HTGC
Next, we examined the relationship between rs4841132-A and HTGC in the DHS where HTGC was measured using 1 H-MRS. (20) No association was found between HTGC and rs4841132-A in the entire cohort ( Fig. 2B) , or after stratifying participants by ethnicity (P > 0.40; Supporting Fig. S1 ). Using a recessive model (AA vs. GG1GA) did not change the null association (P 5 0.37). As shown previously, PNPLA3(148M) was strongly associated with HTGC in the DHS (P 5 3 3 10 -16
; Fig. 2B, right) . (7) Individuals homozygous for the risk variant (148M) had a 2-fold increase in HTGC compared to individuals homozygous for the nonrisk allele (148I). This finding does not support the hypothesis that rs4841132 is associated with HTGC.
ASSOCIATION BETWEEN RS4841132 AND SERUM LIVER ENZYMES
To assess the effect of rs4841132 on hepatic inflammation, we examined the association between the variant and circulating liver enzyme levels. In both the Copenhagen Cohort and the DHS, the A-allele was associated with increased ALT levels ( Fig. 3A ; P trend 5 3 3 10 -4 and 0.004, respectively). A similar, but weaker, association was seen for aspartate aminotransferase (AST) in the larger cohort (P 5 0.04; Supporting Table S1 ), but not in the DHS (P 5 0.27; Supporting Table S2 ). The A-allele was also associated with increased levels of alkaline phosphatase (ALP) in both the DHS (P 5 0.001) and Copenhagen Cohort (P 5 9 3 10 -25 ; Supporting Fig. S2 ). Consistent with these findings, the minor allele of rs6984305, a sequence variant in LD with rs4841132 (r 2 5 0.61), was associated with increased ALT (P 5 0.043) in a large GWAS of serum liver enzymes. (22) No association was found between rs4841132 and serum levels of bilirubin or gamma-glutamyltransferase in either the Copenhagen Cohort (Supporting Table S1 ) or DHS (Supporting Table S2 ). The association of rs4841132-A with increased plasma ALT levels is not consistent with the hypothesis that the allele is associated with protection from FLD.
ASSOCIATION BETWEEN RS4841132 AND NONVIRAL LIVER DISEASE
Given that the rs4841132-A was associated with elevated liver enzymes, we tested whether the variant was associated with increased risk of liver disease. For this analysis, we used two cohorts of patients who had ethnicity-matched controls from the DHS (Fig. 3B) . Patients with viral hepatitis were excluded. In the Copenhagen Cohort, the odds ratio (OR) for liver disease for rs4841132-AA versus -GG homozygotes was 1.91 (95% confidence interval [CI], 1.12-3.26). In both cohorts the rs4841132-A tended toward an association with liver disease, but the association did not reach significance (P 5 0.12) in the Copenhagen Cohort. Excluding individuals with ICD codes specific for NAFLD (n 5 151) and/or alcoholic cirrhosis (n 5 168) did not change the results (data not shown). The trend was significant in the Dallas Liver Study (P 5 0.045), but the CIs for all genotypes included 1. Metaanalysis across the two studies yielded a summary perallele OR of 1.16 (1.03-1.31; P 5 0.01). These data are consistent with an association between the rs4841132-A allele and liver disease.
As a positive control for the cohort, we tested the association of PNPLA3 (148M) with liver disease and plasma ALT levels in the Copenhagen Cohort, the DHS, and the Dallas Liver Study (Supporting Table  S3 ). As expected, the M-allele was robustly associated with elevated ALT (19) and with increased risk of liver disease. observed between rs4841132 and any of the SNPs in either flanking gene: PPP1R3B or TNKS, which encodes tankyrase, a telomere-associated poly-ADP ribose polymerase. Thus, the association between rs4841132 and hepatic glycogen cannot be attributed to LD with a sequence variation in either of the adjacent coding genes.
RS4841132 MAPS TO
As noted above, rs4841132 is located in exon 2 of LOC157273, a liver-specific lncRNA expressed in humans and great apes. LOC157273 resides 175 kb upstream of PPP1R3B and 230 kb upstream of TNKS (Figs. 1C and 4A ). To determine whether the variant is associated with differences in levels of PPP1R3B or TNKS mRNA, we examined an eQTL database (n 5 707 liver samples) collected at Massachusetts General Hospital (Supporting Table S4 ). (23, 24) In that database, the rs4841132-A was associated with a significantly higher level of PPP1R3B mRNA in human livers (P 5 9 3 10 -17
). This finding supports the hypothesis that the minor allele of rs4841132 increases expression of hepatic PPP1R3B, which would be predicted to increase hepatic glycogen synthesis (Fig. 1B) . No association was found between rs4841132-A and TNKS mRNA levels. In the same database, the Aallele was associated with reduced RNA levels of LOC157273 in human liver (P 5 3 3 10 -8
), raising the possibility that effects of rs4841132-A on PPP1R3B are mediated by LOC157273.
To determine whether differences in LOC157273 expression alter PPP1R3B mRNA levels or the glycogen content of cells, we expressed LOC157273 in three human cell lines that synthesize glycogen: embryonic kidney cells (293 cells) (25) and two immortalized human hepatocellular carcinoma cell lines, HepG2 and HuH7-cells. As a positive control, we expressed PPP1R3B in 293 cells, which was associated with a 20-fold increase in cellular glycogen content when compared to cells expressing vector alone (Supporting Fig. S3A ). (13) In contrast, robust expression of LOC157273 (threshold cycle [Ct] values 14-17 by RT-PCR) in the three cell lines failed to alter cellular levels of PPP1R3B mRNA (Ct values 27-31) or glycogen (Supporting Fig. S3B ). Thus, LOC157273 expression appears not to alter expression levels of PPP1R3B, LOC157273 is not conserved in mice, but RNA-sequencing of mouse liver identified an lncRNA in the same region. CRISPR/Cas9 was used to generate mice lacking a 10.6-kb region corresponding to LOC157273, including the mouse lncRNA. (B) Relative levels of hepatic lnc-RNA1, PPP1R3B, and PNPLA3 mRNA assayed by RT-qPCR in fasted mice and 4 hours after refeeding with a chow diet. PNPLA3, which is induced by feeding, (37) served as a positive control in the experiment. (C) Levels of hepatic PPP1R3B mRNA, glycogen, and TG were not significantly different in mice homozygous for the genomic deletion ( 2/2 ) compared to WT controls ( 1/1 ).
or cause changes in glycogen content, at least in these cultured cell lines. LOC157273 is not conserved in mice (Fig. 4A) . To identify transcripts in mice that might serve a function similar to LOC157273, we performed wholetranscriptome analysis of mouse liver and identified transcripts that mapped to the interval between Ppp1r3b and Tnks. An unannotated transcript from the locus, which we have called lncRNA1 (mm10, Chr8: 35206516-35207482) was identified (GenBank Accession ID: MF573324). The transcript is predicted to have a single 967-bp exon and is robustly regulated by food intake (Fig. 4B) .
To determine whether the mouse lncRNA transcribed from the region, or the genomic region per se, plays a functional role in regulating Ppp1r3b, we used CRISPR to generate mice with a 10.6-kb deletion (mm10, Chr8: 35197190-35207767) that included both the lncRNA1 and the genomic region corresponding to human LOC157273. Mice homozygous for the deletion were viable and exhibited no overt phenotype. As anticipated, no lncRNA1 transcript was present in mice homozygous for the deletion (Fig.  4C) . Levels of PPP1R3B mRNA, glycogen, and Tg did not differ in KO mice (Fig. 4C) . Serum glucose levels did not differ between the strains (data not shown). Thus, lncRNA1 and/or the genomic region corresponding to LOC157273 appear not to influence expression of Ppp1r3b or alter hepatic glycogen or fat content in mice.
HEPATIC GLYCOGEN CONTENT WAS REDUCED AND HTGC WAS UNCHANGED IN Ppp1r3b 2/2 MICE
To test the hypothesis that hepatic x-ray attenuation associated with rs4841132-A is attributed to an increase in hepatic glycogen content caused by increased expression of PPP1R3B, we examined the hepatic glycogen and TG levels in livers of mice that either lack (KO) or overexpress PPP1R3B. As we were performing these studies, Rader and his colleagues developed liver-specific Ppp1r3b KO mice. (26) These mice had reduced hepatic glycogen attributed to a reduction in incorporation of glucose into glycogen. Mice also had lower blood glucose levels on both an ad lib diet and after a 4-hour fast. The effect of Ppp1r3b inactivation on liver TG content was not reported.
We used CRISPR to generate mice with a frameshift mutation in Ppp1r3b that is predicted to truncate the protein at residue 22 (p.Pro14Leufs*22). Breeding heterozygous carriers of the deletion yielded 14% homozygotes (Ppp1r3b
) among the offspring (56% Ppp1r3b 1/2 and 30% Ppp1r3b 1/1 ). Despite being born in less than the expected Mendelian ratio, Ppp1r3b 2/2 mice were viable, fertile, and had a similar body weight at 8 weeks. In chow-fed male mice (8 weeks), fed for 4 hours and then killed, hepatic glycogen content was markedly reduced in Ppp1r3b 2/2 mice compared to wild-type (WT) littermates (0.5% vs 4.4% glycogen/liver weight; P < 0.001). HTGC was similar in KO and WT mice (Fig. 5A) . Plasma levels of cholesterol, TG, glucose, and insulin (both fed and fasted for 18 hours) were unchanged ( Fig. 5A and Supporting Fig. S4 ). These findings indicate that variation in Ppp1r3b expression has a major impact on liver glycogen levels, but is not associated with significant changes in HTGC.
ADENOVIRUS-MEDIATED OVEREXPRESSION OF PPP1R3B IN MOUSE LIVER INCREASES GLYCOGEN CONTENT
Overexpression of PPP1R3B in livers of mice and rats is associated with increased hepatic glycogen content. (26, 27) Similarly, we found that adenovirusmediated expression of PPP1R3B at supraphysiological levels in livers of mice caused a dramatic increase in liver weight and hepatic glycogen content (Fig. 5B) . Forty-eight hours after injection of recombinant adenoviruses, livers of mice expressing the mouse PPP1R3B transgene were visibly larger than those injected with the control virus (7.5% vs. 6.0% liver/ body weight; P < 0.001). Hepatic glycogen content was increased in these mice (7.8% vs. 2.4% glycogen/ liver weight; P < 0.001; Fig. 5B ). Levels of hepatic PPP1R3B mRNA were 4-fold higher in mice expressing the PPP1R3B transgene (Ct 5 18 vs. 20; Supporting Fig. S5 ). No changes in HTGC were observed with PPP1R3B overexpression (Fig. 5B) . Plasma levels of ALT, ALP, and cholesterol were increased ( Fig. 5B and Supporting Fig. S5 ) whereas TG levels were reduced in PPP1R3B-treated mice (Fig. 5B) ; plasma levels of glucose and insulin were unchanged in these animals (Supporting Fig. S5 ).
Discussion
The main finding of this study is that the minor Aallele of rs4841132 is associated with increased hepatic x-ray attenuation on CT scan, but not with hepatic fat content. Our data support a model in which rs4841132-A is associated with increased activity of PPP1R3B, an activator of glycogen synthase and inhibitor of glycogen phosphorylase (Fig. 1) . The net effect of the variant is to promote glycogen accumulation in the liver, which increases the attenuation of xrays by this organ. (9) The accumulation of glycogen in carriers of rs4841132-A is associated with elevated circulating levels of ALT and also appears to confer increased susceptibility to liver disease. Observations in mice were consistent with this model: Genetic manipulation of Ppp1r3b activity in mice resulted in large changes in liver glycogen content with no change in HTGC.
In agreement with past studies, we found that variation at the PPP1R3B locus was strongly associated with hepatic x-ray attenuation. (8) However, in our population, the genotype (GG) that was associated with decreased attenuation (consistent with increased fat) was associated with lower plasma ALT levels and reduced risk of liver disease. In contrast, the PNPLA3 FIG. 5. Phenotype of Ppp1r3b KO mice (A) and mice infected with Admouse PPPR1R3B. (A) Food intake was synchronized for 3 days (18-hour fasting, 6-hour feeding) in male mice (8 weeks old, n 5 3-5/group). At the end of the fasting cycle on the 4th day, mice were killed 4 hours after they were fed. The experiment was repeated, and the results were similar. P values by t test. *P < 0.05; **P < 0.001 (B) Phenotype of mice overexpressing mouse PPP1R3B. Tail veins of 8-week-old male mice (10/group) were injected with adenovirusexpressing PPP1R3B (Ad-PPP1R3B) or an empty control virus (Ad-RR5; 1.25 3 10 11 viral particles per mouse). Chow-fed mice were sacrificed 48 hour after the injection. P values by t test. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001.
genotype that was associated with decreased attenuation and increased HTGC was associated with higher ALT levels and with liver disease. These data are consistent with our observation that rs4841132 was not associated with HTGC (Fig. 2) and with previous studies where histology was used to assay hepatic TG. (8, 12) A study in the NHANES III cohort reported an association between the rs4240624 variant and HTGC measured using ultrasonography (OR, 1.28; 95% CI, 1.03-1.59; P 5 0.03). (11) However, the lack of association between liver fat content and PNPLA3 (148M; OR, 1.14; 95% CI, 0.97-1.35) in that study raises concerns about other reported associations. Taken together, the available data support the hypothesis that hepatic glycogen is the factor underlying the robust X-ray attenuation associated with rs4841132-A.
PPP1R3B increases hepatic glycogen accumulation by promoting dephosphorylation and activation of glycogen synthase and dephosphorylation and inactivation of glycogen phosphorylase, the enzymes governing synthesis and breakdown of hepatic glycogen (Fig.  1B) . (28) The finding that rs4841132-A is associated with higher levels of PPP1R3B mRNA in human livers supports the hypothesis that the allele increases hepatic glycogen content by augmenting PPP1R3B activity. (23, 24) The mechanism by which rs4841132 influences the transcription of PPP1R3B is unknown. Intriguingly, rs4841132 maps to exon 2 of the main transcript of LOC157273, a liver-specific lncRNA that is encoded by three exons (NR-040039.1; Fig. 4A ). The mature LOC157273 transcript contains several open reading frames (longest is 119 residues), but these do not appear to be evolutionarily conserved. Could rs4841132 mediate its effect on PPP1R3B expression by LOC157273, as has been documented for regulation of other protein-coding genes by neighboring lncRNAs? Unfortunately, this hypothesis cannot be tested in a small animal model such as mice because LOC157273, like 30% of other lncRNAs, is not present outside of primates. (29) We used whole-transcriptome sequencing of mouse liver RNA to identify transcripts from the locus that might perform the same function as LOC157273. A single exon-containing lncRNA (lncRNA1 in this article) sharing no sequence identity with LOC157273 was regulated in a coordinate fashion with PPP1R3B in response to fasting and refeeding (Fig. 4B) . Noncoding RNAs can be expressed from the same location across species, but share little sequence conservation. (30) We hypothesized that the genomic region per se, or transcriptional activity at the region, might play a functional role in regulating Ppp1r3b. However, genetic deletion of a 10.6-kb genomic region that corresponds to LOC157273 and includes lncRNA1 did not affect Ppp1r3b expression or hepatic glycogen content (Fig. 4C) . Thus, we found no evidence that this transcript, or any other sequences syntenic to LOC157273, affected expression levels of Ppp1r3b.
Rs4841132 is an eQTL for PPP1R3B (minor allele is associated with increased expression) and LOC157273 (decreased expression) in human liver. Thus, the SNP may affect PPP1R3B by altering expression of LOC157273 (i.e., in trans). We examined the effects of expressing LOC157273 in immortalized human hepatocyte cell lines (HuH7, HepG2 cells) where endogenous LOC157273 is expressed at low levels (Ct value, >30). Overexpression of the transcript did not influence mRNA levels of Ppp1r3b or glycogen content (Supporting Fig. S3B) . Thus, the mechanism by which sequence variation at the locus affects PPP1R3B expression, and the role of the lncRNA LOC157273 in this interaction, remains unknown. We suspect that replacing the entire 200-kb genomic region in mice with the corresponding human region might be required to get an experimental handle on this question. (31) To determine whether the associations observed in human carriers of rs4841132 are consistent with what would be expected from perturbing PPP1R3B expression, we generated mice that either lacked or overexpressed the gene and compared their phenotype with the human associations.
While we were performing these studies, Mehta et al. (26) reported that liver-specific Ppp1r3b KO mice had almost no liver glycogen, a slightly more rapid reduction in plasma glucose levels upon acute fasting, and increased plasma ketone levels after prolonged fasting. (26) The phenotypes of these mice are broadly consistent with those of the whole-body Ppp1r3b KO mice studied by us. In addition, we found that HTGC was unchanged in Ppp1r3b KO mice when compared to WT littermates. These data support the hypothesis that genetic variation in PPP1R3B primarily affects hepatic glycogen levels and has little effect on HTGC. Overexpression of PPP1R3B in livers of rats (27) and mice (26) robustly increased hepatic glycogen content. In agreement with these past studies, we found that hepatic overexpression of PPP1R3B in mice caused a marked increase in hepatic glycogen content, and increased plasma markers of liver damage, likely reflecting a glycogen-mediated hepatopathy. HTGC was not affected by PPP1R3B overexpression. Thus, genetic perturbation of PPP1R3B expression in mice changes hepatic glycogen content without affecting HTGC. These observations are consistent with the hypothesis that the increased CT attenuation in human carriers of rs4841132-A is attributed to elevations in hepatic glycogen content and not to changes in HTGC.
Excessive hepatic glycogen accumulation causes liver damage in patients with glycogen storage diseases, (17) but it is not known whether more modest elevations in hepatic glycogen content increase risk of liver disease. There is a clear dose-response relationship between HTGC and liver damage, and even modest increases in HTGC increase risk of liver disease. (19) We found that rs4841132-A was associated with a modest, but statistically significant and reproducible, increase in plasma ALT, a marker of liver injury. Consistent with this observation, the minor allele of rs4240624 (in complete LD with rs4841132) was associated with higher mean ALT among 740 obese Mexicans. (32) We hypothesize that the increase in plasma ALT reflects a mild glycogen-induced hepatopathy.
There are limitations to our study that merit consideration. Definite proof that rs4841132 is glycogenic requires measurement of hepatic glycogen in humans. (33) To our knowledge, hepatic glycogen has not been measured in a large enough sample to detect modest effects. Potential methods to quantitate hepatic glycogen include histology (periodic acid Schiff staining), biochemical measurement in liver biopsies, or 13 C-MRS of the liver in vivo. (33) Assessing the sample size required to detect an association between rs4841132 and hepatic glycogen content is complicated because the effect size of the variant and the natural variation of hepatic glycogen content in human populations are not known. Previous studies found that a 1% increase in biochemically measured hepatic glycogen content increases hepatic x-ray attenuation by 3 HU. (9, 34) Given that the per-allele effect of rs4841132 on x-ray attenuation was 2.4 HU in our study, we estimate that the per-allele effect of rs4841132 on hepatic glycogen content is 0.8% (2.4 HU 3 1% / 3.0 HU). The hepatic glycogen content varies 2-fold within a 24-hour period. (35) In this context, an 0.8% increase (e.g., from 4.0% to 4.8%) appears to be modest. It is therefore likely that a large sample size where feeding status is rigorously controlled will be required to detect association of rs4841132 with hepatic glycogen content.
Another limitation of this study is that the association between rs4841132 and liver disease only reached statistical significance in one of the two liver patient cohorts examined. The association with liver disease will need to be validated in large patient cohorts. Unfortunately, most liver patient cohorts are of European ancestry, and the frequency of rs4841132-A (9% in whites vs. 12% in blacks and 24% in Hispanics), limits the power to detect associations. In a German/ UK GWAS (36) of alcoholic liver disease (n 5 712 alcoholics with cirrhosis and 1,426 alcoholic controls), rs4841132-A was not associated with alcoholic cirrhosis (OR, 0.97; 95% CI, 0.76-1.25). Larger patient cohorts, preferably of Hispanic ancestry, will be required to definitively refute or confirm an association with liver disease.
There were only 1,025 cases with liver disease in the Copenhagen Cohort. Potential explanations for the low prevalence of disease in this population include: (1) the registry-based method of ascertainment selects for symptomatic patients; 2) the median body mass index (BMI) in the Danish cohort was 26 kg/m 2 , lower than in Americans; 3) until recently, NAFLD was underdiagnosed. Nonetheless, the validity of the endpoints used in this article was supported by the finding that PNPLA3 (I148M) was strongly associated with FLD in this study.
Finally, the causal SNP, and the mechanism by which it influences PPP1R3B transcription, remains unknown. We studied rs4841132, but there are several other SNPs at the locus that are in high LD, any of which could contribute to the association. We speculated that the lncRNA, LOC157273, could play a role in mediating the effect of rs4841132 on PPP1R3B transcription. An alternative possibility is that the causal SNP at the locus acts directly on PPP1R3B transcription, and that LOC157273 is irrelevant.
In conclusion, the minor allele of r4841132 is associated with increased hepatic x-ray attenuation and with modestly elevated plasma markers of liver damage. These observations are consistent with the notion that rs4841132 promotes a mild form of hepatic glycogenosis.
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